Two scientists with limited funds, extraordinary dedication and impressive scientific skills are on the brink of making a life-enhancing difference to the treatment of cancer.
Australian scientists Himanshu Brahmbhatt and Jennifer MacDiarmid have been working for 20 years on a discovery that has the potential to revolutionise the treatment of cancer. The pair began their first human trials in Melbourne in 2009 and, over the last 20 years, their company EnGeneIC has conducted trials in Australia and America. Their discovery uses a bacterial nano-cell loaded with chemotherapy to directly target cancer cells while also stimulating a potent anti-tumour immune response. This delivery system eliminates the harmful and life-defeating side effects of chemotherapy. They have called their discovery the EnGeneIC Dream Vector (EDV), and it is a totally new approach to cancer therapy, with enormous potential.
A look behind the scenes during 15 years of extraordinary struggle as scientists Jennifer MacDiarmid and Himanshu Brahmbhatt challenge perceived ideas about how science and business should interface. After years of consistent adversity, they are now in a position of financial and scientific strength that will enable them to take their discovery to market.
